Benzyltryptamine Receptor Selectivity for Lower Cardiotoxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing psychedelic drugs like psilocybin have therapeutic potential for CNS disorders but are limited by cardiotoxic side effects due to 5-HT2B receptor agonist activity, excluding individuals with pre-existing cardiovascular issues from benefiting from their efficacy.
Innovation Solution
Development of novel benzyl-tryptamine compounds, particularly N-methoxybenzyl-tryptamine, which act as 5-HT2A receptor agonists while being antagonists or inactive at the 5-HT2B receptor, reducing the risk of cardiac valvulopathy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If psilocybin is used to treat CNS disorders, then therapeutic efficacy is improved, but cardiotoxic side effects occur due to 5-HT2B receptor agonist activity
Solution Approach 1:
The patent applies local quality by modifying specific positions on the tryptamine molecule (positions 4, 5, and 6 of the indole ring) to create selective agonism at 5-HT2A receptors while eliminating agonist activity at 5-HT2B receptors. This localized structural modification allows the compound to have different pharmacological properties at different receptor targets, achieving therapeutic efficacy without cardiotoxicity
Solution Approach 2:
The patent employs parameter changes by systematically varying substituents at positions 4, 5, and 6 of the indole ring (such as methoxy, hydroxy, halogen, and alkyl groups) to optimize the balance between 5-HT2A agonist activity and 5-HT2B antagonist activity. These chemical parameter modifications enable fine-tuning of receptor selectivity to resolve the contradiction between efficacy and safety
2Reliability
If psilocybin is used to treat CNS disorders, then therapeutic benefits are achieved, but individuals with pre-existing cardiovascular issues are excluded from treatment
Solution Approach 1:
By introducing specific substituents at localized positions (4, 5, 6) of the indole ring, the patent creates compounds with altered receptor profiles that are safe for cardiovascular patients while maintaining therapeutic benefits, thereby expanding treatment accessibility to previously excluded populations
Solution Approach 2:
The patent develops a series of analogs with varying substituent patterns that can be selectively applied based on patient needs, creating a toolkit of compounds with different safety profiles to match different patient populations, including those with cardiovascular conditions
Data Source
AI summary
There is disclosed a compound of Formula (I):and any pharmaceutically acceptable salt or zwitterion thereof, wherein: R is hydrogen, methyl or ethyl; R1 is hydrogen or C1-C2 alkoxy; R2 is methyl or a C2-C4 group which may be saturated or unsaturated, branched or linear; and R3, R4, R5 and R6 each are independently selected from hydrogen, hydroxyl, halogen, methyl optionally substituted with hydroxy, methoxy, ethoxy, and a saturated or unsaturated C2-C3 that may be optionally substituted with hydroxyl, with the provisos that: (i) at least two of R4, R5, R6 and R7 must be hydrogen, and (ii) R3, R4, R5 and R6 may be selected such that an adjacent pair thereof join to form a ring having at least 5 members. The compound of Formula (I) is believed useful in treating a disease or disorder in a subject which may be alleviated by a 5HT2A agonist (e.g., CNS disorders and one or more symptoms of any one of depression, alcoholism, tobacco addiction, cocaine addiction, inflammation, cluster headache and PTSD in a subject).